Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 216

1.

Aspergillus tanneri sp. nov., a new pathogen that causes invasive disease refractory to antifungal therapy.

Sugui JA, Peterson SW, Clark LP, Nardone G, Folio L, Riedlinger G, Zerbe CS, Shea Y, Henderson CM, Zelazny AM, Holland SM, Kwon-Chung KJ.

J Clin Microbiol. 2012 Oct;50(10):3309-17. doi: 10.1128/JCM.01509-12. Epub 2012 Aug 1.

3.

A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility.

Mortensen KL, Johansen HK, Fuursted K, Knudsen JD, Gahrn-Hansen B, Jensen RH, Howard SJ, Arendrup MC.

Eur J Clin Microbiol Infect Dis. 2011 Nov;30(11):1355-63. doi: 10.1007/s10096-011-1229-7. Epub 2011 May 4.

PMID:
21541671
4.

Characterization of clinical strains of Aspergillus terreus complex: molecular identification and antifungal susceptibility to azoles and amphotericin B.

Escribano P, Peláez T, Recio S, Bouza E, Guinea J.

Clin Microbiol Infect. 2012 Feb;18(2):E24-6. doi: 10.1111/j.1469-0691.2011.03714.x. Epub 2011 Nov 30.

5.

Multilocus Phylogeny and Antifungal Susceptibility of Aspergillus Section Circumdati from Clinical Samples and Description of A. pseudosclerotiorum sp. nov.

Siqueira JP, Sutton DA, Gené J, García D, Wiederhold N, Peterson SW, Guarro J.

J Clin Microbiol. 2017 Mar;55(3):947-958. doi: 10.1128/JCM.02012-16. Epub 2017 Jan 4.

6.

Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species.

Misra R, Malik A, Singhal S.

Indian J Pathol Microbiol. 2011 Jan-Mar;54(1):112-6. doi: 10.4103/0377-4929.77352.

7.

In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.

Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG.

J Clin Microbiol. 1999 Jul;37(7):2343-5.

9.

In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp.

Gomez-Lopez A, Garcia-Effron G, Mellado E, Monzon A, Rodriguez-Tudela JL, Cuenca-Estrella M.

Antimicrob Agents Chemother. 2003 Oct;47(10):3085-8.

10.

[In vitro activity of amphotericin B, itraconazole and voriconazole against 20 species of Aspergillus using the Sensititre microdilution method].

García-Martos P, García-Agudo L, Gutiérrez-Calzada J, Ruiz-Aragón J, Saldarreaga A, Marín P.

Enferm Infecc Microbiol Clin. 2005 Jan;23(1):15-8. Spanish.

PMID:
15701327
11.

Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles.

van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-Ossenkopp YJ, Haas PJ, Rijnders BJ, Kuijper EJ, van Tiel FH, Varga J, Karawajczyk A, Zoll J, Melchers WJ, Verweij PE.

Clin Infect Dis. 2013 Aug;57(4):513-20. doi: 10.1093/cid/cit320. Epub 2013 May 10.

PMID:
23667263
12.

In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.

Mallié M, Bastide JM, Blancard A, Bonnin A, Bretagne S, Cambon M, Chandenier J, Chauveau V, Couprie B, Datry A, Feuilhade M, Grillot R, Guiguen C, Lavarde V, Letscher V, Linas MD, Michel A, Morin O, Paugam A, Piens MA, Raberin H, Tissot E, Toubas D, Wade A.

Int J Antimicrob Agents. 2005 Apr;25(4):321-8.

PMID:
15784312
13.

Avian Aspergillus fumigatus strains resistant to both itraconazole and voriconazole.

Beernaert LA, Pasmans F, Van Waeyenberghe L, Dorrestein GM, Verstappen F, Vercammen F, Haesebrouck F, Martel A.

Antimicrob Agents Chemother. 2009 May;53(5):2199-201. doi: 10.1128/AAC.01492-08. Epub 2009 Mar 2.

14.

Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.

Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP.

Diagn Microbiol Infect Dis. 2005 May;52(1):15-20.

PMID:
15878437
15.

Multi-azole resistance in Aspergillus fumigatus.

Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS, Denning DW.

Int J Antimicrob Agents. 2006 Nov;28(5):450-3. Epub 2006 Oct 10.

PMID:
17034993
16.

First determination of azole resistance in Aspergillus fumigatus strains carrying the TR34/L98H mutations in Turkey.

Özmerdiven GE, Ak S, Ener B, Ağca H, Cilo BD, Tunca B, Akalın H.

J Infect Chemother. 2015 Aug;21(8):581-6. doi: 10.1016/j.jiac.2015.04.012. Epub 2015 May 14.

PMID:
26048062
17.

Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009.

Bueid A, Howard SJ, Moore CB, Richardson MD, Harrison E, Bowyer P, Denning DW.

J Antimicrob Chemother. 2010 Oct;65(10):2116-8. doi: 10.1093/jac/dkq279. Epub 2010 Aug 20.

PMID:
20729241
18.

In Vitro Activity of ASP2397 against Aspergillus Isolates with or without Acquired Azole Resistance Mechanisms.

Arendrup MC, Jensen RH, Cuenca-Estrella M.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):532-6. doi: 10.1128/AAC.02336-15.

19.

In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.

Shi JY, Xu YC, Shi Y, Lü HX, Liu Y, Zhao WS, Chen DM, Xi LY, Zhou X, Wang H, Guo LN.

Chin Med J (Engl). 2010 Oct;123(19):2706-9.

PMID:
21034656
20.

Update on antifungal drug resistance mechanisms of Aspergillus fumigatus.

Chamilos G, Kontoyiannis DP.

Drug Resist Updat. 2005 Dec;8(6):344-58. Epub 2006 Feb 20. Review.

PMID:
16488654

Supplemental Content

Support Center